Trial Purpose

The purpose of this study is to compare efficacy of co-formulated favezelimab/pembrolizumab (MK-4280A) with doctor’s choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory, relapsed or refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of co-formulated favezelimab/pembrolizumab. The primary study hypotheses are that co-formulated favezelimab/pembrolizumab is superior to doctor’s choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).

Learn More on ClinicalTrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT05508867

When speaking to your doctor, please have the trial identifier number available.

About The Study

50% will receive MK-4280A coformulation of favelizumab and pembrolizumab

50% will receive chemotherapy

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics, or physician offices.

Trial start Icon

Dates

  • Actual study start date 18 October 2022
  • Estimated primary completion date 16 June 2031
  • Estimated study completion date 16 June 2031

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Hodgkin Lymphoma

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.